Congenital disorders of glycosylation (CDG): state of the art in 2022

Authors:
Top Cited Papers
Open Access
Publisher website
Google Scholar
Abstract
Congenital disorders of glycosylation (CDG) are a complex and heterogeneous family of rare metabolic diseases. With a clinical history that dates back over 40 years, it was the recent multi-omics advances that mainly contributed to the fast-paced and encouraging developments in the field. However, much remains to be understood, with targeted therapies' discovery and approval being the most urgent unmet need. In this paper, we present the 2022 state of the art of CDG, including glycosylation pathways, phenotypes, genotypes, inheritance patterns, biomarkers, disease models, and treatments. In light of our current knowledge, it is not always clear whether a specific disease should be classified as a CDG. This can create ambiguity among professionals leading to confusion and misguidance, consequently affecting the patients and their families. This review aims to provide the CDG community with a comprehensive overview of the recent progress made in this field.
Funding Information
  • FCT - Fundação para a Ciência e a Tecnologia, I.P (UIDP/04378/2020)
  • FCT - Fundação para a Ciência e a Tecnologia, I.P. (UIDB/04378/2020)
  • FCT - Fundação para a Ciência e a Tecnologia, I.P. (LA/P/0140/2020)
  • Portuguese Foundation for Science and Technology (SFRH/BD/138647/2018, SFRH/BD/124326/2016)
  • ProDGNE ((EJPRD/0001/2020 EU 825575)
  • European Commission - GlycoTwinning (101079417)

This publication has 41 references indexed in Scilit: